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Peripherally Inserted Central Catheter-Associated 
Nocardia nova Endocarditis in a Patient Receiving 
Intravenous Antibiotics for Chronic Lyme Disease
Aji B. Njie, Michael Mitchell, and Read Pukkila-Worley
Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
Long-term antibiotics are not effective for the therapy of patients with persistent symptoms and a history of Lyme disease. However, 
some clinicians still prescribe these therapies. We present a case of peripherally inserted central catheter-associated Nocardia nova 
endocarditis in a patient who had been receiving intravenous antibiotics for the management of chronic Lyme disease. This case 
highlights an important risk associated with the unscientific use of indwelling peripheral catheters and intravenous antibiotics for 
the management of such patients.
Keywords.  Nocardia nova endocarditis; Peripherally Inserted Central Catheter-Associated infection; Persistent symptoms and 
a diagnosis of Lyme Disease.
PRESENTATION OF CASE
A 34-year-old female from New England presented with a 
1-month history of daily low-grade fevers, dry cough, loss of ap-
petite, and a 5-pound weight loss. She received 2 separate 5-day 
courses of azithromycin as an outpatient with no improvement 
in her symptoms. Ten years before presentation, the patient 
was diagnosed with Lyme disease. A Western blot for Borrelia 
burgdorferi-specific immunoglobulin IgM antibodies detected 
2 of 3 bands and was interpreted as positive, but a Western blot 
for IgG antibodies was negative. She was treated with doxycy-
cline for 3 weeks. The patient continued to have polyarthralgia 
and fatigue and reported that she was diagnosed with chronic 
Lyme disease 5 years before presentation. She had an indwelling 
peripherally inserted central catheter (PICC) in place for the 
previous 22 months for the administration of intravenous (IV) 
antibiotics that were prescribed to treat chronic Lyme disease. 
She received a 10-month course of IV ceftriaxone and then a 
6-month course of IV doxycycline. She was also prescribed in-
termittent courses of other agents, such as oral disulfuram and 
oral doxycycline, for the treatment of chronic Lyme disease. The 
patient has a history of Ehlers-Danlos syndrome, gastrointes-
tinal malabsorption, which necessitates enteral feeding through 
a nasogastric tube, postural orthostatic tachycardia syndrome, 
and psychogenic nonepileptic seizures. She reported that the 
administration of sulfa drugs caused hives when she was a 
child. On the day of presentation, the patient had a tempera-
ture of 38.1°C and a heart rate of 103 beats per minute. A PICC 
line was in place in the right arm. The rest of her physical exam 
was normal. Kidney function, serum glucose, a complete blood 
count with differential, and liver enzyme tests were all within 
the normal range. Tests for SARS-CoV-2 and human immu-
nodeficiency virus were negative. A  chest x-ray was normal. 
A  chest computed tomography (CT) scan showed multiple 
scattered pulmonary nodules concerning for emboli (Figure 1). 
Branching, Gram-positive bacilli grew in 4 of 4 blood cultures 
bottles taken on the day of her admission to the hospital (Figure 
2). The organism stained with a modified acid-fast bacilli stain 
and was identified as Nocardia nova (Figure 3). The multiple, 
bilateral small nodular opacities seen on CT scan of the chest 
were consistent with septic pulmonary emboli. A transthoracic 
echocardiogram was normal, but transesophageal echocardio-
gram showed a 3-mm × 1-mm mobile vegetation on the mitral 
valve. A  magnetic resonance image of the brain was normal. 
Thus, this patient was diagnosed with PICC-associated N nova 
septic pulmonary emboli and endocarditis.
PATIENT CONSENT
Consent to publish to this case report was obtained from the 
patient. The article type (“ID Teaching Cases”) does not require 
formal approval by an ethics committee.
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DISCUSSION
In this study, we present the case of a patient with a severe com-
plication associated with the unscientific use of IV antibiotics for 
management of persistent symptoms and a diagnosis of Lyme 
disease. Several randomized controlled trials have compared 
long-term antibiotics with placebo for the treatment of these 
patients [1–4]. In each of these studies, longer term antibiotic 
treatment did not improve symptoms in patients compared with 
placebo. However, complications of long-term antibiotic treat-
ment for Lyme disease include PICC-line associated bacteremia, 
which can be life threatening [5]. Despite these data and a rec-
ommendation from the Infectious Diseases Society of America 
against the use of extended courses of antibiotics in this setting 
[6], some clinicians still prescribe such therapies [7, 8].
The patient was initially diagnosed with Lyme disease when 
an immunoblot for B burgdorferi-specific IgM antibodies was 
positive; however, the immunoblot for IgG antibodies was neg-
ative. Borrelia burgdorferi IgM immunoblots have poor speci-
ficity, particularly when the IgG test is negative, and can lead to 
the misdiagnosis of Lyme disease [9]. Thus, an isolated positive 
B burgdorferi IgM immunoblot should not be used to diagnose 
Lyme disease in patients who have had symptoms for more than 
6 weeks.
Nocardia sp are Gram-positive, beaded, weakly acid-fast, 
branching bacilli that are uncommon causes of bacteremia 
and endocarditis [10]. It is interesting to note that N nova was 
the most common pathogen in a case series of patients with 
Nocardia sp bacteremia and an underlying cancer, recovered 
in 6 of 17 cases [11]. Ten of 17 patients in this study had cen-
tral catheter-associated bacteremia, and the authors found that 
Nocardia sp promoted biofilm formation on central venous 
catheters in vitro [11]. Patients with central venous catheter-
associated Nocardia sp bacteremia responded well to catheter 
removal and antibiotic therapy [11].
Data from randomized controlled trials are not available to 
guide treatment for nocardiosis. Based on cumulative clinical 
experience, trimethoprim-sulfamethoxazole is the mainstay of 
therapy for patients with nocardiosis. Patients who are allergic 
to trimethoprim-sulfamethoxazole should be desensitized to 
enable treatment with this agent. Most authorities recommend 
that severe infection with Nocardia sp, such as endocarditis in 
this patient, be managed with combination therapy. For severe 
disease outside the central nervous system, the combination Figure 2. Gram stain of the organism growing in blood culture.
Figure 3. A modified acid-fast bacilli stain of the organism growing in blood 
culture.
Figure 1. Computed tomography of the patient’s chest. Multiple scattered 
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of trimethoprim-sulfamethoxazole and amikacin for initial 
therapy is recommended until antimicrobial susceptibility data 
are available. The combination of imipenem and amikacin is also 
used in this setting. The optimal duration of therapy for patients 
with nocardiosis is not known. Shorter antibiotic courses for 
Nocardia sp infection are associated with a high risk of relapse, 
even in immunocompetent hosts. Thus, most infectious disease 
clinicians recommend that patients with severe nocardiosis be 
treated with antibiotics for 6 to 12 months.
FOLLOW-UP
The patient’s PICC line was removed and she was started 
on imipenem, given her history of a severe allergy to 
trimethoprim-sulfamethoxazole. On the second hospital 
day, the patient’s fever resolved, and her symptoms improved 
markedly. During her hospital stay, she was desensitized 
to trimethoprim-sulfamethoxazole. She was discharged on 
trimethoprim-sulfamethoxazole and amikacin while awaiting 
the identification and susceptibility of the Nocardia sp. Ten days 
into therapy, the patient developed a diffuse maculopapular 
drug rash. The trimethoprim-sulfamethoxazole was discon-
tinued, imipenem was restarted, and the amikacin therapy 
continued. Her rash resolved. After 4 weeks of empiric anti-
biotic treatment, the organism was identified as N nova that 
was sensitive to trimethoprim-sulfamethoxazole, amikacin, 
ceftriaxone, imipenem, and linezolid, but resistant to tetracyc-
lines, fluoroquinolones, and amoxicillin/clavulanate. Imipenem 
and amikacin were discontinued, and the patient was started 
on ceftriaxone, given her history of malabsorption and inability 
to tolerate oral antibiotics. A 6-month course of ceftriaxone is 
planned for this patient, after which a CT scan of the chest will 
be obtained to ensure resolution of the septic emboli. The PICC 
line used to administer ceftriaxone will then be removed.
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